+0.0017(+0.1481%)

Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks

LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VKTX sign up now at www.wallstequities.com/registration. This morning, WallStEquities.com shifts focus on Verastem Inc. (NASDAQ: VSTM), Vericel Corp. (NASDAQ: VCEL), Viking Therapeutics Inc. (NASDAQ: VKTX), and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). According to a report, on May 15th, 2018, Oppenheimer analysts Hartaj Singh and Emma Nealson wrote in a note to clients that the US Biotech sector is likely to improve as the year progresses. "2H18 should be seasonally better for biotech performance, as price increases, fewer rebates/discounts, and medical conference newsflow take effect. We stay bullish," wrote the analysts. All you have to do is sign up today for this free limited time offer by clicking the link below.

Shares in Needham, Massachusetts headquartered Verastem Inc. saw a decline of 3.56%, ending Monday's trading session at $5.14. The stock recorded a trading volume of 2.58 million shares, which was higher than its three months average volume of 1.23 million shares. The Company's shares have gained 18.43% in the last month, 57.67% over the last three months, and 134.70% over the past year. The stock is trading 21.98% and 34.31% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Verastem, which focuses on developing and commercializing drugs for the treatment of cancer, have a Relative Strength Index (RSI) of 57.03.

On May 23rd, 2018, Verastem announced that it has issued 1,166,666 shares of its common stock at a price to the public of $4.50 per share, pursuant to the full exercise of the underwriter's option to purchase additional shares of common stock in connection with the Company's previously announced public offering. The aggregate gross proceeds to Verastem Oncology from the offering, including the full exercise of the underwriter's option, are expected to be $40.2 million. Get the full research report on VSTM for free by clicking below at:

Cambridge, Massachusetts headquartered Vericel Corp.'s stock plummeted 9.72%, closing the day at $13.00. A total volume of 2.14 million shares was traded, which was above their three months average volume of 1.14 million shares. The Company's shares have advanced 9.70% in the previous three months and 329.75% over the past year. The stock is trading 4.78% and 73.97% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Vericel, which researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs, have an RSI of 46.69.

On May 25th, 2018, Vericel announced that Nick Colangelo, President and CEO, will present the latest Company overview at the Jefferies 2018 Global Healthcare Conference on June 08th, 2018, at 2:30 p.m. ET in New York. The live webcast of the presentation may be accessed under the news and events section of the Company's website. Access the free research report on VCEL now by signing up at:

On Monday, shares in San Diego, California headquartered Viking Therapeutics Inc. recorded a trading volume of 5.80 million shares, which was higher than their three months average volume of 2.16 million shares. The stock ended the day 4.31% lower at $9.33. The Company's shares have surged 125.36% in the past month, 45.33% in the previous three months, and 646.40% over the past year. The stock is trading above its 50-day and 200-day moving averages by 94.07% and 141.51%, respectively. Furthermore, shares of Viking Therapeutics, which focuses on the development of novel therapies for metabolic and endocrine disorders, have an RSI of 77.32.

On May 09th, 2018, Viking Therapeutics announced its results for Q1 ended March 31st, 2018. R&D expenses were $3.0 million for Q1 2018; G&A expenses were $1.8 million; and net loss was $3.6 million. At March 31st, 2018, the Company held cash, cash equivalents, and short-term investments totaling $77.5 million.

On June 01st, 2018, research firm Laidlaw reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $10 a share to $15 a share. Are you already registered with Wall St. Equities? Do so now for free, and get the report on VKTX at:

Boston, Massachusetts headquartered ZIOPHARM Oncology Inc.'s stock dropped 8.59%, finishing yesterday's session at $4.47. A total volume of 1.56 million shares was traded, which was above their three months average volume of 1.10 million shares. The Company's shares have advanced 5.18% in the last month and 8.23% in the previous three months. The stock is trading above its 50-day moving average by 1.96%. Additionally, shares of ZIOPHARM Oncology, which focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens, have an RSI of 48.43.

On May 10th, 2018, ZIOPHARM Oncology announced its results for Q1 ended March 31st, 2018. Net loss applicable to the common shareholders for Q1 2018 was $21.1 million, R&D expenses were $10.2 million, and G&A expenses were $6.2 million. The Company ended the quarter with unrestricted cash resources of approximately $51.1 million. Aspiring Member, please take a moment to register below for your free research report on ZIOP at:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: